HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review.

Abstract
Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and panitumumab, have proven efficacy in various types of cancer. However, these agents frequently result in skin toxicity, due to the expression of the EGFR in the skin. A correlation between the occurrence of skin toxicity and anti-tumor activity has been suggested in several phase III studies. However, since skin toxicity may impair the quality of life, and severe skin toxicity requires dose reduction or interruption, adequate and timely management of skin toxicity is important to maximize the anti-tumor efficacy of the EGFR inhibitor, as well as maintaining the patient's quality of life. Due to the small number of randomized controlled trials conducted in the field of EGFR inhibitor-induced skin toxicity so far, it is not possible yet to generate evidence based guidelines on its management. Here, we review and discuss available trials and case studies reporting on the management of EGFR inhibitor-induced skin toxicity.
AuthorsJ M Baas, L L Krens, H-J Guchelaar, J Ouwerkerk, F A de Jong, A P M Lavrijsen, H Gelderblom
JournalCancer treatment reviews (Cancer Treat Rev) Vol. 38 Issue 5 Pg. 505-14 (Aug 2012) ISSN: 1532-1967 [Electronic] Netherlands
PMID22100458 (Publication Type: Journal Article, Review, Systematic Review)
CopyrightCopyright © 2011 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Panitumumab
  • ErbB Receptors
  • Cetuximab
Topics
  • Antibodies, Monoclonal (adverse effects)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Cetuximab
  • ErbB Receptors (antagonists & inhibitors)
  • Humans
  • Neoplasms (drug therapy)
  • Panitumumab
  • Randomized Controlled Trials as Topic
  • Skin (drug effects)
  • Skin Diseases (chemically induced, physiopathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: